Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (NLS), dated November 12, 2024, discloses a proposed merger with Kadimastem Ltd. (Kadimastem). On November 4, 2024, NLS entered into a Merger Agreement whereby Kadimastem will merge into a wholly-owned subsidiary of NLS. The filing provides audited financial statements for Kadimastem for the fiscal year ended December 31, 2023, and unaudited interim statements for the six months ended June 30, 2024, along with pro forma financial statements for the combined entity.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the inclusion of audited and unaudited financial statements for Kadimastem and pro forma statements for the combined entity as exhibits (99.1, 99.2, and 99.3), but the specific figures are not detailed in the provided text.
Material Changes and Transaction Terms
- Merger Structure: Kadimastem will merge with and into NLS Pharmaceutics (Israel) Ltd. (Merger Sub), with Merger Sub as the surviving company.
- Exchange Ratio: Each outstanding ordinary share of Kadimastem will be converted into NLS common shares based on an Exchange Ratio.
- Ownership Impact: The initial Exchange Ratio is estimated to result in Kadimastem shareholders holding approximately 80% of the issued and outstanding shares of NLS on a fully diluted basis, subject to adjustments at closing.
Guidance, Outlook, and Risks
Outlook and Next Steps: NLS intends to file a registration statement on Form F-4, including a joint proxy statement/prospectus, with the SEC. The transaction is contingent upon shareholder approval and regulatory filings. No offer or solicitation of securities is being made in this document.
Risks and Contingencies: The filing explicitly states that this document is not a substitute for the joint proxy statement/prospectus. Investors are urged to read all relevant documents carefully as they contain important information about the proposed transaction. The transaction is subject to adjustments at the time of closing.
Investor Verification Checklist
- Verify the final Exchange Ratio and any adjustments to the 80% ownership estimate for Kadimastem shareholders.
- Review the upcoming Form F-4 joint proxy statement/prospectus for detailed financial data and risk factors.
- Examine the pro forma combined financial statements (Exhibit 99.3) to understand the post-merger financial position.
- Confirm the closing conditions and timeline for the merger.
- Check for any subsequent amendments or supplements filed with the SEC regarding the transaction.